Actively Recruiting
Phase 12 Randomized, Double-Blind Study Evaluating Safety and Immune Response of SCTV02 Recombinant Respiratory Syncytial Virus Vaccine in Healthy Adults 18 Years and Older
Led by Sinocelltech Ltd. · Updated on 2025-02-13
480
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and immune response of a recombinant Respiratory Syncytial Virus RSV vaccine called SCTV02 in adults aged 18 years and older. This randomized, double-blind, placebo-controlled Phase 12 trial aims to assess how well the vaccine works and how safe it is for healthy participants or those with stable underlying conditions. The study is sponsored by Sinocelltech Ltd. and includes monitoring both antibody and T cell responses against RSV subtypes A and B. Participants will receive a single injection of one of three different dose levels of SCTV02 or a matching placebo on Day 0. The study groups include low, medium, and high doses of the vaccine each compared to placebo controls. The trial collects data on adverse events within 7 days solicited and 30 days unsolicited after vaccination. Immunogenicity is assessed through neutralizing antibody levels at multiple time points Day 14, 30, 90, 180, and 365. T cell responses are also measured 30 days after vaccination. During the study, participants will be closely monitored for any side effects and immune responses. They will complete diary cards to record symptoms and attend scheduled visits for blood tests measuring antibody and T cell activity. Researchers will also track serious adverse events for up to one year after vaccination. The trial duration and follow-up provide comprehensive safety and immune response data to evaluate the vaccines potential in adults aged 18 and older.
CONDITIONS
Brief Title
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine
Research Team
Y
Yang Xinjie, Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here